Spruce Biosciences, Inc. Common Stock (SPRB) - Total Liabilities
Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) has total liabilities worth $10.51 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Spruce Biosciences, Inc. Common Stock - Total Liabilities Trend (2018–2025)
This chart illustrates how Spruce Biosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See SPRB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Spruce Biosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Spruce Biosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Impiana Hotels Bhd
KLSE:7243
|
Malaysia | RM192.70 Million |
|
Om Holdings Ltd
AU:OMH
|
Australia | AU$407.98 Million |
|
Manaksia Coated Metals & Industries Limited
NSE:MANAKCOAT
|
India | Rs4.06 Billion |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
USA | $579.63 Million |
|
Waterco Ltd
AU:WAT
|
Australia | AU$134.40 Million |
|
Alpha Cognition Inc
NASDAQ:ACOG
|
USA | $12.39 Million |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
Taiwan | NT$2.87 Billion |
|
Plotech Co Ltd
TW:6141
|
Taiwan | NT$4.67 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Spruce Biosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Spruce Biosciences, Inc. Common Stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Spruce Biosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual total liabilities of Spruce Biosciences, Inc. Common Stock from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.51 Million | -35.90% |
| 2024-12-31 | $16.39 Million | -40.27% |
| 2023-12-31 | $27.44 Million | +59.87% |
| 2022-12-31 | $17.16 Million | +13.54% |
| 2021-12-31 | $15.12 Million | +12.33% |
| 2020-12-31 | $13.46 Million | -61.91% |
| 2019-12-31 | $35.33 Million | +56.48% |
| 2018-12-31 | $22.58 Million | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more